Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health challenge due to the limited efficacy of the Bacillus Calmette-Guérin (BCG) vaccine. Using an immunoinformatics-driven strategy, we designed and evaluated three distinct multi-epitope vaccine constructs (MEVCs) derived from PPE68, IrtA, and PE9, which were subsequently developed into an mRNA vaccine construct. T-cell and B-cell epitopes were predicted using IEDB tools and BepiPred-3.0, and the designed constructs were systematically evaluated for antigenicity, allergenicity, toxicity, and physicochemical characteristics. Structural modeling with AlphaFold3, followed by epitope mapping and molecular docking with TLR2 and TLR4/MD-2, identified Pattern 3 (PPE68-IrtA-PE9) as the most promising construct. It exhibited the highest antigenicity score (0.6122), a high abundance of B-cell epitopes (0.865), and demonstrated predicted binding to the TLR4/MD-2 complex (ΔG =  - 12.2 kcal/mol), forming 12 hydrogen bonds and engaging both receptor components, as well as to TLR2 (ΔG =  - 10.4 kcal/mol) with nine hydrogen bonds. In silico immune simulations of Pattern 3 predicted strong T-cell responses, elevated IFN-γ levels, and high IgG1, IgG2, and IgM titers, while the codon-optimized mRNA exhibited a stable secondary structure (ΔG =  - 2,217.20 kcal/mol). These results suggest that antigen domain arrangement may influence predicted immunogenicity and structural stability, and exhibit a favorable in silico safety profile, supporting PPE68-IrtA-PE9 as a promising mRNA vaccine design for further experimental evaluation.

More information Original publication

DOI

10.1038/s41598-026-47531-5

Type

Journal article

Publication Date

2026-05-11T00:00:00+00:00

Keywords

Epitope prediction, Tuberculosis, Vaccine design, Vaccine immunogenicity, mRNA vaccine